A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.


Updates from The Motley Fool

Latest updates on Alkermes from Fool.com.  The Fool has written over 100 articles on Alkermes.
5 Biotech Predictions for 2016

Image source: Flickr user stockmonkeys.com. Few industries see change as rapidly as biotech, and ...

3 Stocks Scoring for Investors

The Biotech Banter crew is getting into the World Cup spirit, looking at foreign biotechs to se...

This Week in Biotech

With the  SPDR S&P Biotech Index  up 29% over the trailing-12-month period, it's evident that inv...

Tackling Pain and Addiction

Alkermes  (NASDAQ: ALKS) is primarily known for its schizophrenia and multiple sclerosis drug tr...

This Week in Biotech

With the  SPDR S&P Biotech Index  up 31% over the trailing-12-month period, it's evident that inv...

Say Hello to the New Alkermes

It's not easy to reinvent yourself in the biotechnology sector, but that's exactly the path that ...

5 of Last Week's Biggest Winners

What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's b...

This Week in Biotech: Part 2

As I mentioned previously in Part 1 , it was an incredibly busy week for the biotech sector. A PD...



Stock Performance

View Interactive ALKS Charts
Sponsored by

Key Data Points

Primary metrics and data points about Alkermes.
Current Price: $56.25
Prev Close: $54.89
Open: $54.87
Bid: $54.35
Ask: $58.90
Day's Range: $54.37 - $56.73
52wk Range: $27.14 - $80.71
Volume: 892,820
Avg Vol 1,699,920
Market Cap: $8B
P/E (ttm): -32.29
EPS (ttm): ($1.70)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Alkermes.
CAPS Rating 4 out of 5
 
307 Outperform
13 Underperform
CAPS All Stars
 
89 Outperform
3 Underperform

How do you think Alkermes will perform against the market?



You pick for Alkermes is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Richard F. Pops, CEO

100% Approve

Based on 30 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Alkermes.

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers